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Abstract The present study analyzed history of smoking
and willingness to quit smoking in patients referred for
diagnosis and treatment of different oral mucosal lesions.
Prior to the initial clinical examination, patients filled in a
standardized questionnaire regarding their current and
former smoking habits and willingness to quit. Definitive
diagnoses were classified into three groups (benign/reactive
lesions, premalignant lesions and conditions, and malignant
diseases) and correlated with the self-reported data in the
questionnaires. Of the 980 patients included, 514 (52%)
described themselves as never smokers, 202 (21%) as
former smokers, and 264 (27%) as current smokers. In the
group of current smokers, 23% thought their premalignant
lesions/conditions were related to their smoking habit, but
only 15% of the patients with malignant mucosal diseases
saw that correlation. Only 14% of the smokers wanted to
commence smoking cessation within the next 30 days.
Patients with malignant diseases (31%) showed greater
willingness to quit than patients diagnosed with benign/
reactive lesions (11%). Future clinical studies should
attempt (1) to enhance patients’ awareness of the negative
impact of smoking on the oral mucosa and (2) to increase
willingness to quit in smokers referred to a dental/oral
medicine setting.
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Introduction
Smoking harms nearly every organ of the body, leading to a
range of morbidities and premature mortality. There are
some 4,000 known chemicals in tobacco smoke; more than
50 of them are known to cause cancer in humans. The lung
is the site considered at highest relative risk of cancer due
to smoking [1]. Following lung cancer, the highest relative
risks are observed for the larynx and oral cavity [2]. A
recent meta-analysis reported 12 studies that estimated oral
cancer risk in the USA, Uruguay, Italy, Sweden, India,
China, Taiwan, and Korea [3]. The reported pooled cancer
risk estimate was 3.43 times higher in smokers compared
with nonsmokers. Besides oral cancer, other oral diseases
that have been considered related to cigarette smoking
include oral precancer, periodontal disease, caries and tooth
loss, gingival recession, and other benign mucosal disorders
such as smoker’s melanosis and smoker’s palate [4, 5].
Primary prevention focuses on eliminating risk factors in
order to reduce the number of cases of certain diseases.
Since the risk factors for oral cancer and precancer are well
known (tobacco, heavy drinking, poor diet), the oral health
team should act both on the community level as well as in
its clinical environment [6]. In most countries, the simple
scheme of the five As is applied in smoking cessation
efforts: Ask patients about their tobacco habits, Advise
them to quit smoking, Assess patient’s willingness to quit,
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Assist them in achieving this, and Arrange follow-up [7].
The integration and success of tobacco cessation counseling
in a dental practice setting involves changes in the
knowledge, attitudes, and behavior of both dental team
members and their patients. Johnson [8] has identified many
possible barriers to the required changes including lack of
time to spend counseling, lack of training and skills, legal
limitations on prescribing nicotine replacement therapy
(NRT), added costs of the counseling, and client/patient
resistance to quitting smoking.
The aim of the present study was to analyze the willingness
to quit smoking in patients referred to an oral medicine unit for
diagnosis and treatment of different mucosal lesions. Primary
outcome parameters evaluated were a potential relationship
between the type of lesion (benign, premalignant, and
malignant) and a subjective appraisal of patients’ perception
of the benefits following smoking cessation, obtained with a
standardized questionnaire.
Material and methods
Study sample and clinical examination
The present study included all patients referred to the oral
medicine unit at the Department of Oral Surgery and
Stomatology, University of Bern, for diagnosis and treat-
ment of oral mucosal lesions in the period from January
2007 to June 2009. The study protocol was approved by the
standing ethical committee for clinical studies of the
Medical Faculty, University of Bern. All patients were
examined following the same protocol by residents of the
department, including thorough medical history, recent
dental/stomatological history, extraoral and intraoral exam-
ination, and oral biopsy and radiographic imaging where
necessary. Based on the findings of the clinical and
eventual histopathological examinations, a definitive diag-
nosis was formulated and classified in one of three groups:
benign/reactive lesions, premalignant lesions and condi-
tions, or malignant diseases of the oral mucosa. All smokers
underwent brief counseling for smoking cessation (behav-
ioral intervention) including the prescription of NRT
(pharmacological intervention) where indicated, as recom-
mended in the consensus report of the First European
Workshop on Tobacco Use Prevention and Cessation for
Oral Health Professionals [9].
Assessment of smoking status and questionnaire data
■ Before commencement of the initial examination at
the department, all patients had to fill in a standard-
ized questionnaire regarding their current and former
smoking habits and their willingness to quit [10].
This questionnaire included the following parameters:
History of smoking: All patients were asked whether
they were never smokers, former smokers or current
smokers. The current and former smokers had to
indicate the number of cigarettes smoked per day
(including the time period since they started smoking)
to allow for calculation of a pack year value.
■ Current smokers were asked if they thought that their
mucosal problems were related to their smoking
habit. The answers were classified according to the
following index:
0 = No correlation between smoking and mucosal
lesion
1 = Not clear/maybe some relationship between
smoking and mucosal lesion
2 = Clear relationship between smoking and mucosal
lesion
■ Additionally, current smokers were asked whether
they thought their oral lesions would benefit from
smoking cessation. The answers were grouped
according to the following index:
0 = No benefit from smoking cessation
1 = Not clear/maybe some benefit from smoking
cessation
2 = Clear benefit from smoking cessation
■ All smokers were asked if they were willing to quit
smoking, and if so, when they would like to
commence their cessation. The answers were classi-
fied according to the following index:
0 = Not interested in smoking cessation at all
1 = Not interested in smoking cessation at the
moment, maybe in half a year
2 = Interested in smoking cessation during the next
30 days
■ Finally, a history of smoking cessation efforts was
recorded for all smokers, including the use of NRT
(yes/no answer). The following index was used:
0 = No previous smoking cessation effort
1 = One previous smoking cessation effort
2 = Two to four previous smoking cessation efforts
3 = More than four previous smoking cessation efforts
Statistical analysis
First, all data were analyzed using descriptive methods. To
detect significant differences or potential influencing factors
associated with a history of smoking as derived from the
patient questionnaire, we complemented all relevant point
estimates with 95% confidence intervals. Among smokers,
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we estimated the odds ratios for (i) the patient’s willingness
to quit, (ii) the patient’s perception of the benefits of
smoking cessation, and (iii) the patient’s view about any
association between smoking and oral lesions for the three
different types of lesions. In addition, we estimated the 95%
confidence interval of the respective odds ratios. All
statistical analyses were performed using S-Plus Profes-
sional (Insightful Corp., Seattle, WA, USA).
Results
Study population
During the study period from January 2007 to June 2009,
1,044 patients were referred to the oral medicine unit at the
Department of Oral Surgery and Stomatology. A number of
39 patients had to be excluded from further analysis due to
missing data in the smoking status evaluation section of the
questionnaire. Additionally, 25 patients were not included
due to an unclear final diagnosis. Therefore, a total of 980
patients were included in the present study. This group
comprised 453 male and 527 female participants with a
mean age of 55.5 years (minimum 10 years, maximum
96 years).
The definitive diagnoses of the 980 patients included
741 benign/reactive mucosal lesions, 202 premalignant
lesions and conditions, and 37 malignant soft tissue
pathologies. In the group of benign/reactive mucosal
lesions, fibrous hyperplasias were the most frequent finding
(n=138). Also, quite frequent findings were anatomic
variations, with a total of 61 lesions (e.g., geographic
tongue, Fordyce’s spots, etc.). Diagnoses that were encoun-
tered fewer than ten times during the study period included
lesions such as peripheral giant cell granulomas (n=8),
benign mucosal pemphigoid (n=6), and pseudomembra-
nous oral candidosis (n=4). Only five diagnosed malignant
tumors were not squamous cell carcinomas: a distant
metastasis of colon carcinoma and adenocarcinoma of the
lung, a Ewing’s sarcoma, an atypical Burkitt lymphoma,
and an adenoid cystic carcinoma.
Questionnaire analysis
The study population comprised a total of 466 current or
former smokers (48% of 980 patients included). The
percentage of current smokers for the different diagnoses
varied between 0% and 96% of the patients (Table 1).
Regarding the three disease groups (benign/reactive lesions,
premalignant lesions and conditions, and malignant dis-
eases of the oral mucosa), 55% of never smokers had
benign lesions, whereas only 30% had malignant diseases
including oral squamous cell carcinoma (Table 2). The
mean pack year values were 22 for the benign/reactive
lesions group, 30 for premalignant lesions, and 56 for
malignant diseases. The 95% confidence intervals of the
mean indicate that there is a statistically significant increase
in pack years among patients with a malignant lesion.
Current smokers (33%) indicated that they thought
their premalignant lesions/conditions were related to their
smoking habit, yielding an odds ratio of 2.43 (95% CI
1.12–5.27; p<0.01) compared to smokers with a benign
lesion. Only 15% of current smokers with malignant
diseases acknowledged a correlation (Table 3); the odds
ratio as compared to current smokers with benign lesions
was 1.45 (95% CI 0.29–7.09). Asked whether they
thought their oral lesions would benefit from smoking
cessation, 75% of current smokers in the group with
benign/reactive lesions said yes, compared to 57% of
current smokers in the malignant disease group (Table 4).
The odds ratio for patients with malignant versus benign
lesions was therefore 0.45 (95% CI 0.14–1.39). For
patients with a premalignant versus a malignant lesion,
the odds ratio was 1.51 (95% CI 0.71–3.21).
About half of the current smokers (49%) did not want to
quit smoking within the next 6 months. Overall, only 14%
of the smokers wanted to commence smoking cessation
within the next 30 days. There was greater willingness to
quit among smokers with malignant diseases (11% for
benign/reactive versus 31% for malignant lesions; Table 5),
yielding an odds ratio of 3.76 (95% CI 1.03–13.72;
p<0.01). For smokers with a premalignant versus a benign
lesion, the corresponding odds ratio for willingness to quit
was 1.94 (95% CI 0.83–4.52). Accordingly, 38% of the
smokers with malignant mucosal diseases indicated no
interest in quitting smoking, whereas 53% of the smokers
with benign/reactive lesions were not interested.
Regarding history of smoking cessation efforts, 32.5% of
the current smokers reported no previous attempts to stop
smoking. The percentage of smokers who had never before
tried to quit ranged from 25% of current smokers with
premalignant lesions and conditions to 33% of smokers
with benign/reactive lesions to 58% of smokers with
malignant oral lesions (Table 6). Most of the current
smokers that had tried smoking cessation before reported
more than one effort. Out of the 264 registered current
smokers in the study, only 64 had tried NRT for a former
smoking cessation effort.
Discussion
On a global scale, the use of tobacco products is increasing,
although there is a clear trend toward a decrease in high-
income countries. Overall in Europe, the prevalence of
cigarette smoking has stabilized at around 28.6% in the
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adult population (40% males versus 18.2% females), and
there is no visible decline for countries in southern and
eastern Europe such as Greece, with a total of over 50%
smokers (male 63.6%, female 39.8%; [11, 12]). In the
present study, the patients analyzed were rather representa-
tive of an average European population, with 27% being
smokers. Although the patients referred to an oral medicine
unit represent a selective population, and a higher percent-
age of smokers could have been suspected initially, this was
not substantiated by the present findings. Nevertheless,
there was a pronounced difference of percentages of current
smokers present in the three different groups of oral lesions,
with 24% of current smokers having benign/reactive lesions
and 43% of current smokers presenting with malignant
mucosal diseases.
The most important etiological factors for the develop-
ment of oral cancer are tobacco [5], excess consumption of
alcohol [13], and betel quid usage in South and Southeast
Asia [14, 15]. These factors act separately or synergistical-
ly. Heavy drinkers and smokers have 38 times greater risk
than abstainers from both products [16]. In a study from
northern Italy, the single factor with the highest attributable
risk for oral cancer development was smoking [17], and this
risk was related to both intensity and duration of tobacco
smoking [18]. The dose effect of tobacco was also
demonstrated in the present study, where the mean pack
Table 1 Distribution of never, former, and current smokers according to the different mucosal findings (n>10; percentages given, if group total≥
100)
Diagnosis Total Never smoker (%) Former smoker (%) Current smoker (%)
Fibrous hyperplasia 138 79 (57%) 27 (20%) 32 (23%)
Oral lichenoid lesions 112 60 (54%) 38 (34%) 14 (12%)
Oral leukoplakia 100 29 (29%) 14 (14%) 57 (57%)
Oral lichen planus 100 61 (61%) 24 (24%) 15 (15%)
Anatomic variations 61 35 10 16
Frictional hyperkaratosis 53 26 7 20
Oral squamous cell carcinoma 32 9 8 15
Mucocele 31 21 4 6
Papilloma 31 11 6 14
Tobacco-related lesionsa 27 – 1 26
Vascular malformation (e.g., hemangioma) 22 8 11 3
Recurrent aphthous stomatitis 19 11 6 2
Tongue-tie/frenulum 19 19 – –
Sialadenitis/sialolithiasis 18 13 2 3
Burning mouth syndrome (BMS) 18 12 2 4
Pyogenic granuloma 16 10 5 1
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) 15 10 3 2
Amalgam tattoo 12 8 3 1
Lipoma 10 3 3 4
Other lesions (n<10) 146 89 (61%) 28 (19%) 29 (20%)
Total 980 514 (52%) 202 (21%) 264 (27%)
a Smokers’ melanosis and smokers’ palate
Table 2 Distribution of never, former and current smokers according to three different groups of mucosal findings
Group Total Never smoker
(%)
Former
smoker (%)
Current
smoker (%)
Current smokers
male (%)
Current smokers mean py
(95% CI)
Benign/reactive lesion 741 411 (55%) 154 (24%) 176 (24%) 99 (56%) 22 (19–25)
Premalignant lesions and
conditions
202 92 (45.5%) 38 (19%) 72 (35.5%) 43 (60%) 30 (25–35)
Malignant diseases 37 11 (30%) 10 (27%) 16 (43%) 11 (69%) 56 (36–76)
Total 980 514 (52%) 202 (21%) 264 (27%) 153 (58%) –
py Cumulative pack years, defined as 20 manufactured cigarettes/one pack smoked per day for 1 year, CI confidence interval
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year value for current smokers with malignant mucosal
diseases was 56, and the 95% confidence intervals of the
mean indicate that there is a statistically significant increase
in pack years over the three groups of diseases.
Although some studies suggest that smokers know the
potentially harmful effects of smoking such as lung cancer
[19, 20]), there is also literature demonstrating that more
education is needed to inform patients of the other, lesser-
known health risks of cigarette smoking, such as
reproduction-related problems and cancers other than lung
cancer [21–23]. There are few studies assessing patient
awareness of negative effects of cigarette smoking on oral
health. A questionnaire study from 12 dental centers in
Kuwait [24] reported that a majority of included patients
were aware of smoking effects on tooth staining (89.5% of
all subjects). Awareness levels decreased with variables such
as periodontal health (76.2%), oral cancer (62.2%), and
wound healing (27.7%). Fewer smokers than nonsmokers
thought that oral health and smoking are related (92.2% vs.
95.8%) and that smoking affected oral cancer (52.4% vs.
66.8%). Logistic regression analysis showed smokers to be
significantly less aware of the oral health effects of smoking
than nonsmoking patients. Similar results were reported for a
study from the UK questioning 1,000 subjects [25]. In that
survey, 78% of the patients were aware that smoking had a
negative impact on health. However, 52% of patients who
were aware of the negative impact could not state what the
negative effects were on oral health. Similar findings were
also reported for another study asking 152 patients after
treatment for oral cancer about their smoking habits, alcohol
consumption, and their understanding of the part these
factors play in the development of malignancy [26]. At least
6 months after the diagnosis of their malignancy, 72 (47%)
still smoked and 55 (36%) drank alcohol to excess. Only one
third were aware that their addiction had an impact on the
development of oral cancer.
In the present study, only 14% of the smokers questioned
indicated that they thought there was a clear relationship
Table 3 Correlation between the smoking habit and the mucosal findings as assessed by the current smokers in the three groups of diseases
analyzed
Correlation smoking and mucosal lesion
Group 0 (% and 95% CI) 1 (% and 95% CI) 2 (% and 95% CI) Row total
Benign/reactive lesion 108 (67% and ±7.2%) 36 (22% and ±6.4%) 18 (11% and ±4.8%) 162b
Premalignant lesions and conditions 24 (40% and ±12.4%) 22 (37% and ±12.9%) 14 (23% and ±10.7%) 60c
Malignant diseasesa 8 (62% and ±26.4%) 3 (23% and ±22.9%) 2 (15% and ±19.6%) 13d
Column total 140 (60%) 61 (26%) 34 (14%) 235
0 No correlation between smoking and mucosal lesion, 1 not clear/maybe some relationship between smoking and mucosal lesion, 2 clear
relationship between smoking and mucosal lesion, 95% CI 95% confidence interval
a Group comprises 12 squamous cell carcinomas and one distant metastasis of an adenocarcinoma of the lung
b Answers missing: 14
c Answers missing: 12
d Answers missing: 3
Table 4 Potential benefit of smoking cessation as estimated by the current smokers in the three groups of diseases analyzed
Benefit of smoking cessation on mucosal lesion
Group 0 (% and 95% CI) 1 (% and 95% CI) 2 (% and 95% CI) Row total
Benign/reactive lesion 18 (12% and ±5.3%) 19 (13% and ±5.5%) 109 (75% and ±7.6% 146b
Premalignant lesions and conditions 8 (13% and ±8.6%) 3 (5% and ±5.5%) 49 (82% and ±9.8%) 60c
Malignant diseasesa 1 (7% and ±13.5%) 5 (36% and ±25.1%) 8 (57% and ±25.9%) 14d
Column total 27 (12%) 27 (12%) 166 (76%) 220
0 No benefit from smoking cessation, 1 not clear/maybe some benefit from smoking cessation, 2 clear benefit from smoking cessation, 95% CI
95% confidence interval
a Group comprises 13 squamous cell carcinomas and one distant metastasis of an adenocarcinoma of the lung
b Answers missing: 30
c Answers missing: 12
d Answers missing: 2
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between smoking and their mucosal lesion. But in contrast
to the studies mentioned above, the patients were not
knowledgeable about the definite diagnosis when answer-
ing the questionnaire before the initial clinical examination.
All they knew about their respective mucosal findings was
what the referring dentist had told them. Interestingly,
patients with premalignant conditions/lesions were more
aware of a correlation between smoking and their mucosal
lesion, exhibiting a statistically significant odds ratio of
2.43 (95% CI 1.12–5.27, p<0.01) as compared to patients
with a benign lesion.
The significance of dentists’ role in supporting their
patients’ attempts to discontinue tobacco use was first
mentioned by Christen [27]. Since this initial report,
tobacco use interventions in the dental setting have
consistently shown to increase the odds of quitting [7, 28,
29]. Additionally, although patients expect their oral health
care providers to ask about their tobacco use history [30–
32], many dental professionals express discomfort about
implementing tobacco use prevention and cessation
(TUPAC) strategies in their routine care. These barriers
include the possibility of dental patients being offended by
discussions of smoking cessation and therefore account for
the reason that only 33–50% of dentists routinely ask their
patients about their tobacco dependence [7]. Other barriers
to the implementation of TUPAC have been identified such
as (i) lack of financial incentives or resources, (ii)
assumptions that patients will not cooperate, (iii) tobacco
use by oral health professionals, (iv) frustration over low
success rates, (v) lack of visible effects of tobacco use in
the oral cavity, (vi) low cost–benefit ratio, and (vii)
discomfort in discussing tobacco use cessation [7, 8].
In order to potentially reduce these barriers and to
facilitate the adoption of TUPAC strategies by dental
practitioners, a level of care model involving a step-by-
step strategy was recently proposed in the consensus report
of the 2nd European Workshop on Tobacco Use Prevention
and Cessation for Oral Health Professionals, to give dental
clinicians the freedom to offer a varied approach, according
to their patients’ needs [33, 34]. Following this approach, in
Table 5 Willingness to quit smoking reported by the current smokers in the three groups of mucosal lesions analyzed
Willingness to quit smoking
Group 0 (% and 95% CI) 1 (% and 95% CI) 2 (% and 95% CI) Row total
Benign/reactive lesion 75 (53 and ±8.2%) 52 (36.5 and ±7.9%) 15 (10.5 and ±5.0%) 142b
Premalignant lesions and conditions 24 (40.5 and ± 12.5%) 24 (40.5 and ±12.5%) 11 (19 and ±9.9%) 59c
Malignant diseasesa 5 (38 and ±26.4%) 4 (31 and ±25.1%) 4 (31 and ±25.1%) 13d
Column total 104 (49%) 80 (37%) 30 (14%) 214
0 Not interested in smoking cessation at all, 1 not interested in smoking cessation at the moment, maybe in half a year, 2 interested in smoking
cessation during the next 30 days, 95% CI 95% confidence interval
a Group comprises 12 squamous cell carcinomas and one distant metastasis of an adenocarcinoma of the lung
b Answers missing: 34
c Answers missing: 13
d Answers missing: 3
Table 6 Previous smoking cessation efforts of the current smokers in the population evaluated
Smoking cessation efforts
Group 0 1 2 3 Row total
Benign/reactive lesion 50 (33%) 38 (25%) 49 (32%) 14 (10%) 151b
Premalignant lesions and conditions 15 (25%) 14 (24%) 24 (41%) 6 (10%) 59c
Malignant diseasesa 7 (58%) 2 (17%) 2 (17%) 1 (8%) 12d
Column total 72 (32.5%) 54 (24.5%) 75 (33.5%) 21 (9.5%) 222
0 No previous smoking cessation effort, 1 one previous smoking cessation effort, 2 two to four previous smoking cessation efforts, 3 more than
four previous smoking cessation efforts
a Group comprises 11 squamous cell carcinomas and one distant metastasis of an adenocarcinoma of the lung
b Answers missing: 25
c Answers missing: 13
d Answers missing: 4
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the oral medicine unit at the School of Dental Medicine,
University of Bern, every patient is offered basic TUPAC
care consisting of brief interventions to identify tobacco
users, assess readiness to quit, request permission to
readdress at a subsequent visit, and if preferred, refer for
further TUPAC counseling.
In the present study population, there was greater
willingness to quit smoking in patients with malignant
diseases (11% for benign/reactive versus 31% for malignant
lesions), yielding a statistically significant odds ratio of
3.76 (95% CI 1.03–13.72, p<0.01). An inverse trend can be
seen regarding the history of previous smoking cessation
efforts, where the percentage of smokers who had never
tried to stop smoking ranged from 25% of the current
smokers with premalignant lesions and conditions to 33%
of the smokers with benign/reactive lesions to 58% of the
questioned smokers with malignant oral lesions.
To the best of our knowledge, the present study
represents the first approach in the literature to assess
patients’ awareness of a possible relationship between their
smoking habit and the mucosal disorders present, and their
willingness to quit smoking. Nevertheless, the data pre-
sented has to be interpreted with some caution, as patients
may have been already informed about the nature of their
mucosal lesion (benign/reactive, premalignant, malignant),
and its possible correlation with the harmful effects of
smoking by their referring dentist. Furthermore, the study
did not include smokeless tobacco in the questionnaire,
thus, potentially underestimating the actual use of tobacco
products by the patients evaluated. Future studies should
take these possible confounders into account and should
also try to validate subjective questionnaire data concerning
tobacco use with objective methods, e.g., carbon monoxide
or cotinine blood level testing. Whether current results for
TUPAC [35–37] can be improved through more targeted
identification of patients ready to quit smoking and the
provision of alternate cessation strategies—including phar-
macotherapy such as bupropion or varenicline—remains to
be demonstrated in prospective clinical studies.
Conclusions
The present study demonstrates that patients referred to an
oral medicine unit for treatment of a variety of oral mucosal
diseases represent a percentage of current smokers (27%)
similar to that of the general Swiss population. Only a
minority of the smokers questioned (14%) saw a clear
relationship between their smoking habit and the mucosal
lesion present, whereas a majority (76%) indicated that
there could be a benefit from smoking cessation on the oral
mucosa. Only 14% of the smokers were interested in
undertaking a smoking cessation effort during the next
30 days, but there was significantly greater willingness to
quit among patients with malignant diseases (odds ratio of
3.76) in comparison to patients with benign/reactive
lesions. Future clinical studies should attempt (1) to
enhance patients’ awareness of the negative impact of
smoking on the oral mucosa and (2) to increase willingness
to quit in smokers referred to a dental/oral medicine setting.
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